Page 21 - ARNM-3-2

Advances in Radiotherapy
& Nuclear Medicine Role of PET/CT in exploring tumor heterogeneity

Transl Med. 2021;9:16. doi: 10.1186/s13244-022-01186-8
doi: 10.21037/atm-21-1948 15. Zhao S, Kuge Y, Mochizuki T, et al. Biologic correlates of
5. Jönsson H, Ahlström H, Kullberg, J. Spatial mapping of intratumoral heterogeneity in 18 F-FDG distribution
tumor heterogeneity in whole-body PET-CT: A feasibility with regional expression of glucose transporters and
study. Biomed Eng Online. 2023;22:110. hexokinase-II in the experimental tumor. J Nucl Med.
2005;46:675-682.
doi: 10.1186/s12938-023-01173-0
16. Derlon JM, Chapon F, Noel MH, et al. Non-invasive
6. Hughes NM, Mou T, O’Regan KN, et al. Tumor heterogeneity grading of oligodendrogliomas: Correlation between in vivo
measurement using [18F] FDG PET/CT shows prognostic metabolic pattern and histopathology. Eur J Nucl Med.
value in patients with non-small cell lung cancer. Eur J 2000;27:778-787.
Hybrid Imaging. 2018;2:25.
doi: 10.1007/s002590000260
doi: 10.1186/s41824-018-0043-1
17. Henriksson E, Kjellen E, Wahlberg P, et al. 2-Deoxy-2-[ 18
7. McQuerry JA, Chang JT, Bowtell DDL, Cohen A, Bild AH. F] fluoro-D-glucose uptake and correlation to intratumoral
Mechanisms and clinical implications of tumor heterogeneity heterogeneity. Anticancer Res. 2007;27:2155-2159.
and convergence on recurrent phenotypes. J Mol Med (Berl).
2017;95:1167-1178. 18. Van Baardwijk A, Bosmans G, Van Suylen RJ, et al.
Correlation of intra-tumour heterogeneity on 18 F-FDG
doi: 10.1007/s00109-017-1587-4 PET with pathologic features in nonsmall cell lung cancer:
8. Li C, Wang S, Li C, Yin Y, et al. Improved risk stratification A feasibility study. Radiother Oncol. 2008;87:55-58.
by PET-based intratumor heterogeneity in children with doi: 10.1016/j.radonc.2008.02.002
high-risk neuroblastoma. Front Oncol. 2022;12:896593.
19. Eary JF, O’Sullivan F, O’Sullivan J, Conrad EU. Spatial
doi: 10.3389/fonc.2022.896593 heterogeneity in sarcoma 18F-FDG uptake as a predictor of
9. Marusyk A, Polyak K. Tumor heterogeneity: Causes and patient outcome. J Nucl Med. 2008;49:1973-1979.
consequences. Biochim Biophys Acta. 2010;1805:105-117. doi: 10.2967/jnumed.108.053397
doi: 10.1016/j.bbcan.2009.11.002 20. Kidd EA, Grigsby PW. Intratumoral metabolic heterogeneity
10. Morrissy AS, Cavalli FMG, Remke M, et al. Spatial of cervical cancer. Clin Cancer Res. 2008;14:5236-5241.
heterogeneity in medulloblastoma. Nat Genet. 2017;49: doi: 10.1158/1078-0432.CCR-07-5252
780-788.
21. Tixier F, Le Rest CC, Hatt M, et al. Intratumor heterogeneity
doi: 10.1038/ng.3838 characterized by textural features on baseline 18F-FDG PET
11. Savas P, Teo ZL, Lefevre C, et al. The subclonal architecture images predicts response to concomitant radiochemotherapy
of metastatic breast cancer: Results from a prospective in esophageal cancer. J Nucl Med. 2011;52:369-378.
community-based rapid autopsy program “CASCADE”. doi: 10.2967/jnumed.110.082404
PLoS Med. 2016;13:e1002204.
22. Schinagl DA, Kaanders JH, Oyen WJ. From anatomical
doi: 10.1371/journal.pmed.1002204. Erratum in: PLoS Med. to biological target volumes: The role of PET in radiation
2017;14(4):e1002302. treatment planning. Cancer Imaging. 2006;6:107-116.
doi: 10.1371/journal.pmed.1002302 doi: 10.1102/1470-7330.2006.9017
12. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and 23. Newbold KL, Partridge M, Cook G, et al. Evaluation of the
resistance to cancer therapies. Nat Rev Clin Oncol. role of 18FDG-PET/CT in radiotherapy target definition
2018;15:81-94.
in patients with head and neck cancer. Acta Oncol.
doi: 10.1038/nrclinonc.2017.166 2008;47:1229-1236.
13. Bailly C, Bodet-Milin C, Bourgeois M, et al. Exploring doi: 10.1080/02841860802256483.
tumor heterogeneity using PET imaging: The big picture. 24. Lopci E, Nanni C, Castellucci P, et al. Imaging with non-
Cancers (Basel). 2019;11:1282. FDG PET tracers: Outlook for current clinical applications.
doi: 10.3390/cancers11091282 Insights Imaging. 2010;1:373-385.
14. Anan N, Zainon R, Tamal M. A review on advances in doi: 10.1007/s13244-010-0040-9
18 F-FDG PET/CT radiomics standardization and application 25. Jadvar H, Delgado-Bolton R, Nadel H, et al. Appropriate
in lung disease management. Insights Imaging. 2022;13:22. use criteria for F-FDG PET/CT in restaging and treatment
18
doi: 10.1186/s13244-021-01153-9. Erratum in: Insights response assessment of malignant disease. J Nucl Med.
Imaging. 2022;13(1):32. 2017;58:2026-3724.

Volume 3 Issue 2 (2025) 13 doi: 10.36922/ARNM025040005